Ana Sayfa
Piyasalar
Grafikler ve Fikirler
Algo
Haberler
Store
Aracı Kurumlar
İndir
Ekonomik Takvim
Alım-Satım Sinyalleri
Web Terminali
Heatmap
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
LYEL
#2840
Lyell Immunopharma, Inc. Common Stock
24.105
0
USD
-2.80%
Sektör:
Sağlık Hizmetleri
Baz:
USD
Kar Para Birimi:
USD
Günlük Aralık
Yıllık Aralık
Günlük Değişim
-2.80%
Aylık Değişim
+12.80%
6 aylık değişim
-0.35%
Yıllık Değişim
-0.35%
Önceki Kapanış
24.800
0
Open
24.200
0
Bid
Ask
Low
24.090
0
High
24.270
0
Hacim
8
Piyasalar
ABD Borsası
Sağlık Hizmetleri
LYEL
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
12.27 M
12.48 M
12.7 M
14.76 M
23.31 M
—
Valuation ratios
Enterprise value
1.61 B
715.13 M
390.5 M
83.35 M
657.21 M
987.81 M
Price to earnings ratio
-4.21
-4.54
-2.27
-0.49
-1.92
-3.42
Price to sales ratio
0.1
9.8
4 073.65
2 743.4
14.61 K
24.8 K
Price to cash flow ratio
-0.01
-4.9
-3.24
-1.03
-3.51
-6.49
Price to book ratio
0
1
0.81
0.44
2.12
2.46
Enterprise value to EBITDA ratio
-7.98
-4.23
-1.72
-0.25
-2.55
-3.54
Profitability ratios
Return on assets %
-0.22
-0.2
-0.31
-0.7
-0.81
-0.74
Return on equity %
-0.27
-0.22
-0.36
-0.9
-1.11
-0.98
Return on invested capital %
-127.37
-129.16
-275.12
-562.33
-869.26
—
Gross margin %
100
100
100
100
100
400
Operating margin %
-2 016.68
-220.89
-190.01 K
-588.12 K
-748.34 K
-3.78 M
EBITDA margin %
-1 888.75
-199.61
-174.43 K
-555.94 K
-716.29 K
-3.64 M
Net margin %
-2 349.47
-216.24
-180.49 K
-562.29 K
-762.36 K
-3.88 M
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
13.4
17.59
16.07
7.06
5.28
30.71
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
0.08
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-18.58 K
-13.72
-13.04
-12.42
-8.78
-9.49
EBIT per share
-31.6 K
-15.14
-19.68
-27.44
-15.76
-16.58
EBITDA per share
-29.6 K
-13.68
-18.07
-25.94
-15.09
-15.86
Total debt per share
—
—
—
—
—
—
Cash per share
90.62 K
51.82
43.53
28.34
14.46
71.08
Net current asset value per share
92.16 K
52.72
44.2
29.03
15.27
73.26
Tangible book value per share
136.82 K
67.45
52.19
29.28
14.52
75.55
Working capital per share
85.28 K
49.72
41.45
24.92
12.38
63.34
Book value per share
136.82 K
67.45
52.19
29.28
14.52
75.55
Haberler
Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst - TipRanks.com
Morning News Wrap-Up 4/10/26: Today’s Biggest Stock Market Stories! - TipRanks.com
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL)
H.C. Wainwright, Lyell Immunopharma hissesi için al önerisini korudu
Citizens, Lyell Immunopharma hissesi için tavsiyesini korudu
Citizens reiterates Lyell Immunopharma stock rating on trial progress
Avago, Lumentum among market cap stock movers on Monday
Lyell Immunopharma 50 milyon dolarlık hisse satışını tamamladı
Lyell Immunopharma closes $50M equity tranche, names new CFO
Citizens, Lyell Immunopharma hissesini üstün performans ile başlattı, hedef 34 dolar
Citizens initiates Lyell Immunopharma stock at outperform, $34 target
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript